These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34430345)

  • 1. Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study.
    Mathilakathu A; Borchert S; Wessolly M; Mairinger E; Beckert H; Steinborn J; Hager T; Christoph DC; Kollmeier J; Wohlschlaeger J; Mairinger T; Schmid KW; Walter RFH; Brcic L; Mairinger FD
    Transl Lung Cancer Res; 2021 Jul; 10(7):3030-3042. PubMed ID: 34430345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.
    Walter RF; Vollbrecht C; Werner R; Mairinger T; Schmeller J; Flom E; Wohlschlaeger J; Barbetakis N; Paliouras D; Chatzinikolaou F; Adamidis V; Tsakiridis K; Zarogoulidis P; Trakada G; Christoph DC; Schmid KW; Mairinger FD
    J Cancer; 2016; 7(13):1915-1925. PubMed ID: 27698933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

  • 4. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
    Ting S; Mairinger FD; Hager T; Welter S; Eberhardt WE; Wohlschlaeger J; Schmid KW; Christoph DC
    Clin Lung Cancer; 2013 Sep; 14(5):558-567.e3. PubMed ID: 23810210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.
    Kim K; Ko Y; Oh H; Ha M; Kang J; Kwon EJ; Kang JW; Kim Y; Heo HJ; Kim G; Kim JW; Kim YH
    J Toxicol Environ Health A; 2020 Feb; 83(3):126-134. PubMed ID: 32114955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study.
    Chollet B; Guinde J; Laroumagne S; Dutau H; Astoul P
    Thorac Cancer; 2021 Jun; 12(11):1752-1756. PubMed ID: 33949775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
    Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
    Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
    BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
    BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with 
Malignant Pleural Mesothelioma].
    Zeng X; Jiang Z; Duan J
    Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.
    Paajanen J; Ilonen I; Lauri H; Järvinen T; Sutinen E; Ollila H; Rouvinen E; Lemström K; Räsänen J; Ritvos O; Koli K; Myllärniemi M
    Clin Lung Cancer; 2020 May; 21(3):e142-e150. PubMed ID: 31734071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.
    Kuroda A; Matsumoto S; Fukuda A; Nakamichi T; Nakamura A; Hashimoto M; Takuwa T; Kondo N; Tsujimura T; Nakano T; Hasegawa S
    Anticancer Res; 2019 Nov; 39(11):6241-6247. PubMed ID: 31704853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.
    Mairinger FD; Werner R; Flom E; Schmeller J; Borchert S; Wessolly M; Wohlschlaeger J; Hager T; Mairinger T; Kollmeier J; Christoph DC; Schmid KW; Walter RFH
    Virchows Arch; 2017 Jun; 470(6):627-637. PubMed ID: 28466156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.
    Walter RF; Vollbrecht C; Werner R; Wohlschlaeger J; Christoph DC; Schmid KW; Mairinger FD
    Oncotarget; 2016 Apr; 7(14):18713-21. PubMed ID: 26918730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
    Milosevic V; Kopecka J; Salaroglio IC; Libener R; Napoli F; Izzo S; Orecchia S; Ananthanarayanan P; Bironzo P; Grosso F; Tabbò F; Comunanza V; Alexa-Stratulat T; Bussolino F; Righi L; Novello S; Scagliotti GV; Riganti C
    Int J Cancer; 2020 Jan; 146(1):192-207. PubMed ID: 31107974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
    Remon J; Reguart N; Corral J; Lianes P
    Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.